ES2323936T3 - Vacunas dtpa mucosicas. - Google Patents
Vacunas dtpa mucosicas. Download PDFInfo
- Publication number
- ES2323936T3 ES2323936T3 ES00962770T ES00962770T ES2323936T3 ES 2323936 T3 ES2323936 T3 ES 2323936T3 ES 00962770 T ES00962770 T ES 00962770T ES 00962770 T ES00962770 T ES 00962770T ES 2323936 T3 ES2323936 T3 ES 2323936T3
- Authority
- ES
- Spain
- Prior art keywords
- antigen
- pertussis
- vaccine
- intranasal
- tetanus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 229960005486 vaccine Drugs 0.000 title description 46
- 239000000427 antigen Substances 0.000 claims abstract description 49
- 108091007433 antigens Proteins 0.000 claims abstract description 49
- 102000036639 antigens Human genes 0.000 claims abstract description 49
- 201000005702 Pertussis Diseases 0.000 claims abstract description 26
- 239000003814 drug Substances 0.000 claims abstract description 24
- 206010013023 diphtheria Diseases 0.000 claims abstract description 15
- 206010043376 Tetanus Diseases 0.000 claims abstract description 14
- 229940079593 drug Drugs 0.000 claims abstract description 13
- 238000002255 vaccination Methods 0.000 claims abstract description 12
- 238000004519 manufacturing process Methods 0.000 claims abstract description 11
- 230000000977 initiatory effect Effects 0.000 claims description 13
- 108010021711 pertactin Proteins 0.000 claims description 4
- 229960000814 tetanus toxoid Drugs 0.000 claims description 4
- 229930186900 holotoxin Natural products 0.000 claims description 3
- 229960003983 diphtheria toxoid Drugs 0.000 claims description 2
- 206010011224 Cough Diseases 0.000 claims 1
- 101710154643 Filamentous hemagglutinin Proteins 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 description 34
- 241000699670 Mus sp. Species 0.000 description 28
- 230000004044 response Effects 0.000 description 28
- 241000588832 Bordetella pertussis Species 0.000 description 15
- 101150026046 iga gene Proteins 0.000 description 15
- 238000007918 intramuscular administration Methods 0.000 description 13
- 210000004072 lung Anatomy 0.000 description 13
- 102000004388 Interleukin-4 Human genes 0.000 description 12
- 108090000978 Interleukin-4 Proteins 0.000 description 12
- 108010002616 Interleukin-5 Proteins 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 230000002787 reinforcement Effects 0.000 description 12
- 229940037003 alum Drugs 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 10
- 239000000203 mixture Substances 0.000 description 10
- 235000018102 proteins Nutrition 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 210000002966 serum Anatomy 0.000 description 10
- 102000004127 Cytokines Human genes 0.000 description 8
- 108090000695 Cytokines Proteins 0.000 description 8
- 210000001165 lymph node Anatomy 0.000 description 8
- 230000005867 T cell response Effects 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 230000003053 immunization Effects 0.000 description 7
- 238000002649 immunization Methods 0.000 description 7
- 210000000952 spleen Anatomy 0.000 description 7
- 210000001744 T-lymphocyte Anatomy 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 230000008030 elimination Effects 0.000 description 5
- 238000003379 elimination reaction Methods 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 239000003053 toxin Substances 0.000 description 5
- 231100000765 toxin Toxicity 0.000 description 5
- 108700012359 toxins Proteins 0.000 description 5
- 108010071134 CRM197 (non-toxic variant of diphtheria toxin) Proteins 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 210000004989 spleen cell Anatomy 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- 206010002091 Anaesthesia Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 102100037850 Interferon gamma Human genes 0.000 description 3
- 108010074328 Interferon-gamma Proteins 0.000 description 3
- 230000006052 T cell proliferation Effects 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000003472 neutralizing effect Effects 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 210000000115 thoracic cavity Anatomy 0.000 description 3
- 230000005730 ADP ribosylation Effects 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 229920001661 Chitosan Polymers 0.000 description 2
- 229940032024 DPT vaccine Drugs 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
- 229940032047 Tdap vaccine Drugs 0.000 description 2
- 230000000240 adjuvant effect Effects 0.000 description 2
- 230000003444 anaesthetic effect Effects 0.000 description 2
- 230000005875 antibody response Effects 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
- 235000021240 caseins Nutrition 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 2
- 229960003132 halothane Drugs 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 229940066827 pertussis vaccine Drugs 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- 208000008771 Lymphadenopathy Diseases 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 210000000447 Th1 cell Anatomy 0.000 description 1
- 210000004241 Th2 cell Anatomy 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- NFXWJYUDIOHFAW-UHFFFAOYSA-N acetic acid;tetradecanoic acid Chemical compound CC(O)=O.CCCCCCCCCCCCCC(O)=O NFXWJYUDIOHFAW-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 229940030156 cell vaccine Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940028617 conventional vaccine Drugs 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 230000017307 interleukin-4 production Effects 0.000 description 1
- 230000022023 interleukin-5 production Effects 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical class CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 235000021239 milk protein Nutrition 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- 230000001459 mortal effect Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 229940100652 nasal gel Drugs 0.000 description 1
- 229940052404 nasal powder Drugs 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 238000009666 routine test Methods 0.000 description 1
- 238000006748 scratching Methods 0.000 description 1
- 230000002393 scratching effect Effects 0.000 description 1
- 238000010845 search algorithm Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 101150063569 slgA gene Proteins 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 239000012646 vaccine adjuvant Substances 0.000 description 1
- 229940124931 vaccine adjuvant Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
- A61K39/0018—Combination vaccines based on acellular diphtheria-tetanus-pertussis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/099—Bordetella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55544—Bacterial toxins
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/832—Drug, bio-affecting and body treating compositions involving bacterial toxin that has modified amino acid sequence
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/82—Proteins from microorganisms
- Y10S530/825—Bacteria
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9923060 | 1999-09-29 | ||
| GBGB9923060.9A GB9923060D0 (en) | 1999-09-29 | 1999-09-29 | Vaccine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2323936T3 true ES2323936T3 (es) | 2009-07-28 |
Family
ID=10861826
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES00962770T Expired - Lifetime ES2323936T3 (es) | 1999-09-29 | 2000-09-28 | Vacunas dtpa mucosicas. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US7279169B1 (https=) |
| EP (1) | EP1223975B1 (https=) |
| JP (2) | JP5025867B2 (https=) |
| AT (1) | ATE431744T1 (https=) |
| CA (1) | CA2386023C (https=) |
| CY (1) | CY1110327T1 (https=) |
| DE (1) | DE60042243D1 (https=) |
| DK (1) | DK1223975T3 (https=) |
| ES (1) | ES2323936T3 (https=) |
| GB (1) | GB9923060D0 (https=) |
| PT (1) | PT1223975E (https=) |
| WO (1) | WO2001022993A2 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9326174D0 (en) * | 1993-12-22 | 1994-02-23 | Biocine Sclavo | Mucosal adjuvant |
| WO2002080982A2 (en) | 2001-01-12 | 2002-10-17 | Chiron Corporation | Nucleic acid mucosal immunization |
| GB0302218D0 (en) | 2003-01-30 | 2003-03-05 | Chiron Sri | Vaccine formulation & Mucosal delivery |
| NZ536859A (en) * | 2002-05-14 | 2007-11-30 | Chiron Srl | Mucosal combination vaccines for bacterial meningitis |
| AU2010203223B9 (en) | 2009-01-05 | 2015-10-08 | Epitogenesis Inc. | Adjuvant compositions and methods of use |
| AR077636A1 (es) * | 2009-07-08 | 2011-09-14 | Abbott Biologicals Bv | Vacuna viral y uso de la misma |
| CN107837394A (zh) | 2011-06-24 | 2018-03-27 | 埃皮托吉尼西斯有限公司 | 作为抗原特异性免疫调节剂的包含选择的载体、维生素、单宁和类黄酮的组合的药物组合物 |
| JP5966018B2 (ja) * | 2011-12-21 | 2016-08-10 | バイオネット−エイジア，カンパニー・リミテッド | 改変ボルデテラ・パータシス株 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2849632B2 (ja) | 1988-04-08 | 1999-01-20 | 社団法人北里研究所 | ワクチン製剤 |
| IT1248735B (it) | 1990-06-21 | 1995-01-26 | Sclavo Spa | Vaccini acellulari contro la pertosse |
| GB9513371D0 (en) | 1995-06-30 | 1995-09-06 | Biocine Spa | Immunogenic detoxified mutant toxins |
| IT1253009B (it) | 1991-12-31 | 1995-07-10 | Sclavo Ricerca S R L | Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini |
| GB9209118D0 (en) * | 1992-04-28 | 1992-06-10 | Sb 120 Amsterdam Bv | Vaccine compositions |
| FI945483A7 (fi) | 1992-05-23 | 1995-01-20 | Smithkline Beecham Biologicals S A | Hepatiitti B - pinta-antigeenejä ja muita antigeenejä sisältäviä yhdistelmärokotteita |
| DK0616034T3 (da) * | 1993-03-05 | 2005-02-21 | Wyeth Corp | Plasmid til fremstilling af CRM-protein og diphtheria toxin |
| JP3752264B2 (ja) * | 1995-02-24 | 2006-03-08 | 財団法人化学及血清療法研究所 | 混合ワクチン |
| GB9622133D0 (en) | 1996-10-24 | 1996-12-18 | Niotech Limited | Inverter circuits |
| US5980898A (en) * | 1996-11-14 | 1999-11-09 | The United States Of America As Represented By The U.S. Army Medical Research & Material Command | Adjuvant for transcutaneous immunization |
| US7115730B1 (en) * | 1999-04-27 | 2006-10-03 | Chiron Srl | Immunogenic detoxified mutant E. coli LT-A-toxin |
-
1999
- 1999-09-29 GB GBGB9923060.9A patent/GB9923060D0/en not_active Ceased
-
2000
- 2000-09-28 DE DE60042243T patent/DE60042243D1/de not_active Expired - Lifetime
- 2000-09-28 AT AT00962770T patent/ATE431744T1/de active
- 2000-09-28 PT PT00962770T patent/PT1223975E/pt unknown
- 2000-09-28 CA CA2386023A patent/CA2386023C/en not_active Expired - Fee Related
- 2000-09-28 DK DK00962770T patent/DK1223975T3/da active
- 2000-09-28 JP JP2001526202A patent/JP5025867B2/ja not_active Expired - Fee Related
- 2000-09-28 EP EP00962770A patent/EP1223975B1/en not_active Expired - Lifetime
- 2000-09-28 ES ES00962770T patent/ES2323936T3/es not_active Expired - Lifetime
- 2000-09-28 WO PCT/IB2000/001440 patent/WO2001022993A2/en not_active Ceased
- 2000-09-28 US US10/089,367 patent/US7279169B1/en not_active Expired - Fee Related
-
2009
- 2009-08-12 CY CY20091100868T patent/CY1110327T1/el unknown
-
2012
- 2012-01-05 JP JP2012000806A patent/JP2012067137A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| ATE431744T1 (de) | 2009-06-15 |
| EP1223975B1 (en) | 2009-05-20 |
| JP2012067137A (ja) | 2012-04-05 |
| GB9923060D0 (en) | 1999-12-01 |
| PT1223975E (pt) | 2009-08-26 |
| DK1223975T3 (da) | 2009-08-31 |
| CA2386023A1 (en) | 2001-04-05 |
| WO2001022993A2 (en) | 2001-04-05 |
| WO2001022993A3 (en) | 2001-10-25 |
| CA2386023C (en) | 2011-04-26 |
| US7279169B1 (en) | 2007-10-09 |
| CY1110327T1 (el) | 2015-01-14 |
| EP1223975A2 (en) | 2002-07-24 |
| DE60042243D1 (de) | 2009-07-02 |
| JP5025867B2 (ja) | 2012-09-12 |
| JP2003510292A (ja) | 2003-03-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2273391T3 (es) | Composicion de vacuna para administracion a una superficie mucosal. | |
| ES2139879T5 (es) | Adyuvante de la mucosa no toxico. | |
| AU648509B2 (en) | Stable vaccine compositions containing interleukins | |
| JP3911058B2 (ja) | ストレプトコックス エキワクチン | |
| Roberts et al. | A mutant pertussis toxin molecule that lacks ADP-ribosyltransferase activity, PT-9K/129G, is an effective mucosal adjuvant for intranasally delivered proteins | |
| Locht | Will we have new pertussis vaccines? | |
| Sugai et al. | A CpG-containing oligodeoxynucleotide as an efficient adjuvant counterbalancing the Th1/Th2 immune response in diphtheria–tetanus–pertussis vaccine | |
| Anggraeni et al. | Development of mucosal vaccine delivery: an overview on the mucosal vaccines and their adjuvants | |
| ES2257769T3 (es) | Metodo para la preparacion de vacunas multivalentes. | |
| Isaka et al. | Induction of systemic and mucosal antibody responses in mice immunized intranasally with aluminium-non-adsorbed diphtheria toxoid together with recombinant cholera toxin B subunit as an adjuvant | |
| JP2012067137A (ja) | 粘膜ＤＴＰａワクチン | |
| WO2005049076A1 (es) | Polisacáridos capsulares de neisseria meningitidis como inmunopotenciadores mucosales y formulaciones resultantes | |
| TW201440786A (zh) | 無細胞百日咳疫苗 | |
| KR20030015288A (ko) | 보조제 배합물로서의 큐에스-21 및 아이엘-12 | |
| ES2275495T3 (es) | Formulacion de la vacuna contra la tuberculosis que contiene como adyuvante monogliceridos o acidos grasos. | |
| AU725137B2 (en) | Bordetella strain expressing the hybrid FHA, liposomes and vaccines | |
| CN111701018A (zh) | 环二核苷酸修饰铝纳米粒疫苗佐剂-传递系统 | |
| BR112021007668A2 (pt) | composições imunogênicas | |
| Cropley et al. | Mucosal and systemic immunogenicity of a recombinant, non-ADP-ribosylating pertussis toxin: effects of formaldehyde treatment | |
| Mirchamsy et al. | Stimulating role of toxoids-laden liposomes in oral immunization against diphtheria and tetanus infections | |
| Levine et al. | Mucosal immunization and needle-free injection devices | |
| Kiyono et al. | Nasopharyngeal and oral immune system | |
| Bowersock et al. | Vaccine Delivery Systems | |
| Saadh et al. | Vaccines: Purified Macromolecules as Vaccines and DNA Vaccines. | |
| Rüssmann et al. | IgA/IgM and secretory immunity |